FDA ap­proves Mer­ck­'s Keytru­da for be­fore and af­ter lung can­cer surgery

Mer­ck’s megablock­buster can­cer drug Keytru­da (pem­brolizum­ab) won a high­ly sought-af­ter FDA ap­proval as the first check­point in­hibitor to treat pa­tients with ear­ly-stage non-small cell lung …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER